Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

CD13 is a bona-fide marker of bovine pre-adipocytes with potential in cultivated fat applications.

Lee S., Thrower T., Riley SE., Esteves CL., Donadeu FX.

Laboratory Study with a reported sample of 5 on Face & Skin, published in NPJ Sci Food (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
NPJ Sci Food (2026)
Country
England
Reported sample size
5
Source database
PubMed
PMID
41530199
PMCID
PMC12901004
DOI
10.1038/s41538-026-00711-z

Abstract (original English)

Despite its significant potential, cultivated fat manufacture remains a relatively inefficient process, as it primarily uses source preparations of animal-derived mesenchymal stem/stromal cells (MSC) that are poorly defined and highly heterogenous in nature, containing only relatively minor fractions of bona-fide adipocyte progenitors. The aim of this study was to use RNA-sequencing of clonal MSC populations from cattle to identify cell surface marker(s) of bona-fide pre-adipocytes to be used for efficient enrichment of MSCs, with a view to future cultivated fat applications. Adipose-derived MSC populations (n = 5 animals) were grown clonally from single cells and subsequently tested for adipogenic capacity. Adipogenic (A) and non-adipogenic (N) clones (n = 10/group) thus identified were bulk RNA-sequenced. A total of 35 cluster of differentiation (CD) genes were identified among differentially expressed transcripts, of which CD13, CD141, CD36, CD55 and CD34 were selected for further testing using flow cytometry in bovine MSCs. All antigens except CD13 were detected at negligible levels. FACS was then used to sort MSCs (n = 4 animals) into CD13+ and CD13- fractions. Sorted CD13+ cells were larger and flatter, grew significantly slower, and expressed substantially higher levels of adipogenic regulators (PPARG and CEBPA) compared to CD13- cells. Moreover, on average, adipogenic e

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research